Have you or your loved ones been diagnosed with acute myeloid leukemia (aml)?

You may be eligible to participate in a acute myeloid leukemia (aml) clinical trial.

Have you or your loved ones been diagnosed with acute myeloid leukemia (aml)? You may be eligible to participate in a acute myeloid leukemia (aml) clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Acute Myeloid Leukemia (AML) Clinical Trial in Pierre-Benite Rhone
NCT02752035 | Phase 3 | Interventional

Have you or your loved ones been diagnosed with acute myeloid leukemia (aml)?

You may be eligible to participate in a acute myeloid leukemia (aml) clinical trial.

Have you or your loved ones been diagnosed with acute myeloid leukemia (aml)? You may be eligible to participate in a acute myeloid leukemia (aml) clinical trial.

Active not recruiting

Male & Female

18 Years +

This study has recruited 183 Participants

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some patients with AML have a mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called FLT3. This protein causes the leukemia cells to grow faster. For patients with AML who cannot receive standard chemotherapy, azacitidine (also known as Vidaza®) is a current standard of care treatment option in the United States. This clinical study is testing an experimental medicine called ASP2215, also known as gilteritinib. Gilteritinib works by stopping the leukemia cells from making the FLT3 protein. This can help stop the leukemia cells from growing faster. This study will compare two different treatments. Patients are assigned to one of these two groups by chance: a medicine called azacitidine, also known as Vidaza®, or an experimental medicine gilteritinib in combination with azacitidine. There is a twice as much chance to receive both medicines combined than azacitidine alone. The clinical study may help show which treatment helps patients live longer.